Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Biomater Sci ; 8(9): 2590-2599, 2020 May 06.
Artículo en Inglés | MEDLINE | ID: mdl-32238997

RESUMEN

In this work we describe the formulation and characterisation of red-emitting polymeric nanocapsules (NCs) incorporating superparamagnetic iron oxide nanoparticles (SPIONs) for magnetic tumour targeting. The self-fluorescent oligomers were synthesised and chemically conjugated to PLGA which was confirmed by NMR spectroscopy, FT-IR spectroscopy and mass spectrometry. Hydrophobic SPIONs were synthesised through thermal decomposition and their magnetic and heating properties were assessed by SQUID magnetometry and calorimetric measurements, respectively. Magnetic nanocapsules (m-NCs) were prepared by a single emulsification/solvent evaporation method. Their in vitro cytotoxicity was examined in CT26 colon cancer cells. The formulated fluorescent m-NCs showed good stability and biocompatibility both in vitro and in vivo in CT 26 colon cancer models. Following intravenous injection, accumulation of m-NCs in tumours was observed by optical imaging. A higher iron content in the tumours exposed to a magnetic field, compared to the contralateral tumours without magnetic exposure in the same animal, further confirmed the magnetic tumour targeting in vivo. The overall results show that the engineered red-emitting m-NCs have great potential as multifunctional nanocarriers for multi-model bioimaging and magnetic-targeted drug delivery.


Asunto(s)
Compuestos Férricos/administración & dosificación , Colorantes Fluorescentes/administración & dosificación , Nanocápsulas/administración & dosificación , Neoplasias/diagnóstico por imagen , Neoplasias/terapia , Animales , Línea Celular Tumoral , Sistemas de Liberación de Medicamentos , Femenino , Compuestos Férricos/farmacocinética , Colorantes Fluorescentes/farmacocinética , Hipertermia Inducida , Hierro/metabolismo , Fenómenos Magnéticos , Ratones Endogámicos BALB C , Neoplasias/metabolismo , Polietilenglicoles/administración & dosificación , Polietilenglicoles/farmacocinética , Poliglactina 910/administración & dosificación , Poliglactina 910/farmacocinética , Distribución Tisular
2.
J Control Release ; 264: 219-227, 2017 Oct 28.
Artículo en Inglés | MEDLINE | ID: mdl-28867377

RESUMEN

We study the influence of ultrasound on paclitaxel-loaded nanocapsules in vitro and in vivo. These nanocapsules possess a shell of poly(dl-lactide-co-glycolide)-poly(ethylene glycol) (PLGA-PEG) and a liquid core of perfluorooctyl bromide (PFOB). In vitro experiments show that mechanical effects such as cavitation are negligible for nanocapsules due to their small size and thick and rigid shell. As the mechanical effects were unable to increase paclitaxel delivery, we focused on the thermal effects of ultrasound in the in vivo studies. A focused ultrasound sequence was therefore optimized in vivo under magnetic resonance imaging guidance to obtain localized mild hyperthermia with high acoustic pressure. Ultrasound-induced mild hyperthermia (41-43°C) was then tested in vivo in a subcutaneous CT-26 colon cancer murine model. As hyperthermia is applied, an inhibition of tumor growth for both paclitaxel-loaded nanocapsules and the commercial formulation of paclitaxel, namely Taxol® have been observed (p<0.05). Ultrasound-induced mild hyperthermia at high acoustic pressure appears as an interesting strategy to enhance cytotoxic efficacy locally.


Asunto(s)
Antineoplásicos Fitogénicos/administración & dosificación , Hipertermia Inducida , Nanocápsulas/administración & dosificación , Paclitaxel/administración & dosificación , Terapia por Ultrasonido , Animales , Antineoplásicos Fitogénicos/farmacocinética , Antineoplásicos Fitogénicos/uso terapéutico , Línea Celular Tumoral , Terapia Combinada , Femenino , Fluorocarburos/administración & dosificación , Fluorocarburos/farmacocinética , Fluorocarburos/uso terapéutico , Hidrocarburos Bromados , Ratones Desnudos , Nanocápsulas/uso terapéutico , Neoplasias/metabolismo , Neoplasias/terapia , Paclitaxel/farmacocinética , Paclitaxel/uso terapéutico , Polietilenglicoles/administración & dosificación , Polietilenglicoles/farmacocinética , Polietilenglicoles/uso terapéutico , Poliglactina 910/administración & dosificación , Poliglactina 910/farmacocinética , Poliglactina 910/uso terapéutico , Distribución Tisular , Resultado del Tratamiento
3.
Nanomedicine (Lond) ; 10(11): 1723-33, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25706349

RESUMEN

AIM: Provide an enhanced local drug delivery, nanoparticle(s) to minimize systemic effects and achieve enhanced permeability and drug retention into abnormal cells and stroma. MATERIALS & METHODS: Here a simultaneous loading of lipophilic gold nanorods (GNRs) and curcumin into polymeric nanomicelles made of biocompatible PLGA-b-PEG copolymer through a double re-emulsification process has been developed. RESULTS: Initial results in vitro on Barrett's esophagus and esophageal adenocarcinoma cell lines demonstrated a significant reduction in cell viability with curcumin and GNRs exposure (p < 0.05). In vivo Barrett's-associated animal model confirmed these results with successful in vivo demonstrated eradication of all high-grade dysplastic premalignant cancer cells. CONCLUSION: The synthesis of this novel nanosystem containing GNRs and curcumin is safe and effective in treating and eradicating premalignant esophageal adenocarcinoma.


Asunto(s)
Esófago de Barrett/tratamiento farmacológico , Curcumina/administración & dosificación , Sistemas de Liberación de Medicamentos , Nanotubos/efectos adversos , Animales , Esófago de Barrett/patología , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Curcumina/química , Esófago/efectos de los fármacos , Oro/administración & dosificación , Oro/química , Humanos , Micelas , Nanotubos/química , Fototerapia , Polietilenglicoles/administración & dosificación , Polietilenglicoles/química , Poliglactina 910/administración & dosificación , Poliglactina 910/química , Ratas
4.
Pharm Dev Technol ; 18(5): 1078-88, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-22656315

RESUMEN

OBJECTIVE: The aim of this study was to investigate the effect of two mechanistically different porogens, namely: the hydrophilic hydroxy-propyl-ß-cyclodextrin and the hydrophobic porogens (mineral oil and corn oil) in producing open/closed pored engineered polylactide-co-glycolic-acid microspheres suitable for pulmonary delivery of risedronate sodium (RS). MATERIALS AND METHODS: Surface morphology of the microspheres was studied and they were characterized for entrapment efficiency (%EE), particle size, and porosity as well as aerodynamic and flow properties. Selected formulae were investigated for in vitro drug release and deposition behavior using next generation impactor. Furthermore, the safety of the free drug and the selected prepared systems was assessed by MTT viability test performed on Calu-3 cell line. RESULTS AND DISCUSSION: The current work revealed that HP-ß-CD produced open-pored microspheres, while oils produced closed pored microspheres. Modulation of preparation parameters generated porous RS microspheres with high %EE, sustained drug release profile up to 15 days, suitable geometric and aerodynamic particle sizes and excellent flow properties. The safety of HP-ß-CD systems was higher than the systems utilizing oil as porogen. CONCLUSION: Porogen type affected the behavior of the microspheres as demonstrated by the various characterization experiments, with microspheres prepared using HP-ß-CD being superior to those prepared using oils as porogens.


Asunto(s)
Ácido Etidrónico/análogos & derivados , Poliglactina 910/química , Línea Celular , Aceite de Maíz/química , Ácido Etidrónico/administración & dosificación , Ácido Etidrónico/química , Humanos , Interacciones Hidrofóbicas e Hidrofílicas , Microesferas , Aceite Mineral/química , Tamaño de la Partícula , Poliglactina 910/administración & dosificación , Porosidad , Ácido Risedrónico , beta-Ciclodextrinas/administración & dosificación , beta-Ciclodextrinas/química
5.
Bioorg Med Chem ; 20(11): 3502-22, 2012 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-22546206

RESUMEN

To identify topically effective EP4 agonists and EP2/EP4 dual agonists with excellent subtype selectivity, further optimization of the 16-phenyl ω-chain moiety of the γ-lactam 5-thia prostaglandin E analog and the 2-mercaptothiazole-4-carboxylic acid analog were undertaken. Rat in vivo evaluation of these newly identified compounds as their poly (lactide-co-glycolide) microsphere formulation, from which sustained release of the test compound is possible, led us to discover compounds that showed efficacy in a rat bone fracture healing model after its topical administration without serious influence on blood pressure and heart rate. A structure-activity relationship study is also presented.


Asunto(s)
Lactamas/síntesis química , Lactamas/farmacología , Prostaglandinas E Sintéticas/síntesis química , Prostaglandinas E Sintéticas/farmacología , Subtipo EP2 de Receptores de Prostaglandina E/agonistas , Subtipo EP4 de Receptores de Prostaglandina E/agonistas , Administración Tópica , Animales , Presión Sanguínea/efectos de los fármacos , Células CHO , Cricetinae , Preparaciones de Acción Retardada/administración & dosificación , Preparaciones de Acción Retardada/química , Dinoprostona/química , Evaluación Preclínica de Medicamentos/métodos , Curación de Fractura/efectos de los fármacos , Frecuencia Cardíaca/efectos de los fármacos , Lactamas/administración & dosificación , Masculino , Ratones , Microesferas , Estructura Molecular , Poliglactina 910/administración & dosificación , Poliglactina 910/química , Ratas , Ratas Sprague-Dawley , Relación Estructura-Actividad , Tiazolidinas/química
6.
Curr Drug Deliv ; 7(4): 263-73, 2010 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-20695837

RESUMEN

Long term prevention of smooth muscle cell migration and proliferation inside the lumen of coronary arteries after stent implantation remains a challenge in medicine. Vascular stents have been coated with anti-proliferative drugs such as paclitaxel and rapamycin to improve the stents' efficacy. Maintaining adequate drug concentration on coronary stents presents an obstacle which magnetic nanoparticle (MNP) drug delivery could potentially overcome. Biodegradable, super-paramagnetic nanoparticles guided by high gradient magnetic fields have been proposed as transport vehicles for re-dosing stents with anti-proliferative drugs. The current study determined the characteristics of a number of candidate MNP formulations in terms of their size, surface charge, efficiency of magnetite and drug loadings, drug release profiles as well as their anti-proliferative effect on the relevant vascular cells. MNPs containing near 30% (w/w) magnetite and 12% (w/w) paclitaxel were formulated from polylactide and poly(lactide-co-glycolide) polymers using an emulsification-solvent evaporation methodology. Drug release patterns correlated well with cell growth inhibition in cultured aortic smooth muscle cells and bovine aortic endothelial cells treated with varying MNP doses. Cell viability assays revealed MNP dose-dependent cell growth inhibition over an 8-day time span for paclitaxel-loaded formulations resulting in near 80% and 100% of cell growth arrest in cultured vascular smooth muscle cells and endothelial cells respectively, while unloaded with drug formulations showed negligible variation from the non treated cells. It is concluded, that biodegradable polymeric superparamagnetic nanoparticles loaded with a relatively high level of magnetite and drug could serve as efficient carriers in vascular stent targeting applications and potentially allow re-dosing the depleted stents, thereby prolonging the lifecycle of the implant.


Asunto(s)
Proliferación Celular/efectos de los fármacos , Sistemas de Liberación de Medicamentos/métodos , Óxido Ferrosoférrico/administración & dosificación , Paclitaxel/administración & dosificación , Animales , Bovinos , Células Cultivadas , Química Farmacéutica/métodos , Evaluación Preclínica de Medicamentos , Óxido Ferrosoférrico/síntesis química , Óxido Ferrosoférrico/química , Magnetismo , Paclitaxel/farmacología , Tamaño de la Partícula , Poliglactina 910/administración & dosificación , Poliglactina 910/química , Polímeros/administración & dosificación , Polímeros/química , Ratas , Propiedades de Superficie
7.
J Orthop Res ; 24(3): 327-32, 2006 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-16479565

RESUMEN

To produce an osteogenic and bacteriocidal biomaterial for the treatment of infected nonunions or bone defects, a synthetic degradable block copolymer of poly-D,L-lactic acid segments with randomly inserted p-dioxanone and polyethylene glycol (PLA-DX-PEG) segments was mixed with recombinant human BMP-2 (rhBMP-2) and antibiotics at high concentration. We then examined the in vitro elution profile of an antibiotic (teicoplanin) from the polymer, the effects of antibiotics on the bone-inducing capacity of rhBMP-2 or on ectopic new bone formation induced by the rhBMP, and the ability of the polymer to repair bone in a rat cranial defect model. Approximately 40% of teicoplanin was released within the first 24 h, with the remaining amount released steadily over 21 days with no loss of antibacterial activity. The polymer had disappeared by degradation in the phosphate buffered saline (pH 7.4) at the end of the incubation period. The in vivo performance of pellets with antibiotics and rhBMP-2 revealed no significant change in bone yield within the ossicles after 3 weeks. Also, antibiotics had no inhibitory effect on the ability of rhBMP2 to repair cranial defects. Indeed, when the defect was filled by a polymer disc loaded with rhBMP-2 with or without teicoplanin, the defect was repaired by new bone, and normal anatomy was restored within 6 weeks. In conclusion, the PLA/DX/PEG polymer appears to work as effectively for antibiotics as it does for rhBMP-2. Additionally, the biological activity of rhBMP-2 was retained irrespective of the presence of antibiotics.


Asunto(s)
Implantes Absorbibles , Antibacterianos/administración & dosificación , Proteínas Morfogenéticas Óseas/administración & dosificación , Portadores de Fármacos , Proteínas Recombinantes/administración & dosificación , Factor de Crecimiento Transformador beta/administración & dosificación , Cicatrización de Heridas/efectos de los fármacos , Animales , Antibacterianos/farmacocinética , Proteína Morfogenética Ósea 2 , Modelos Animales de Enfermedad , Implantes Experimentales , Masculino , Pruebas de Sensibilidad Microbiana , Oseointegración/efectos de los fármacos , Poliglactina 910/administración & dosificación , Ratas , Ratas Wistar , Cráneo/efectos de los fármacos , Cráneo/lesiones , Cráneo/patología
8.
Clin Orthop Relat Res ; (267): 237-44, 1991 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-2044286

RESUMEN

Successful treatment of chronic osteomyelitis requires sustained high concentrations of antibiotics locally within the infected bone. The efficacy of biodegradable (poly-DL-lactide-co-glycolide) microspheres containing 30.7% ampicillin anhydrate for the local treatment of experimental staphylococcal osteomyelitis was evaluated in rabbits. In the initial experiment, antibiotic therapy was initiated immediately following injection of Staphylococcus aureus into the proximal tibial metaphysis. A single intramedullary injection of microencapsulated ampicillin (100 mg) prevented osteomyelitis in all seven animals tested and was as effective as a two-week course of parenteral ampicillin administration. When antibiotic therapy was delayed for seven days, osteomyelitis developed in four of eight animals treated locally with microencapsulated ampicillin and in six of eight animals that received parenteral ampicillin therapy. When antibiotic therapy was delayed for seven days and was preceded by debridement, all ten animals treated locally with microencapsulated ampicillin had sterile bone cultures. In contrast, seven of ten animals treated locally with unencapsulated ampicillin powder developed osteomyelitis. Biodegradable antibiotic-loaded microspheres may be of clinical benefit for the local treatment of chronic osteomyelitis.


Asunto(s)
Ampicilina/uso terapéutico , Osteomielitis/tratamiento farmacológico , Poliglactina 910/administración & dosificación , Infecciones Estafilocócicas/tratamiento farmacológico , Ampicilina/administración & dosificación , Animales , Biodegradación Ambiental , Cápsulas , Desbridamiento , Portadores de Fármacos , Evaluación Preclínica de Medicamentos , Osteomielitis/microbiología , Osteomielitis/prevención & control , Conejos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA